Mucolytics - Macomb
Download
Report
Transcript Mucolytics - Macomb
Mucolytics
Module E
Mucolysis
• Mucolysis is the breakdown of mucus.
• Mucolysis is needed in diseases in which
there is increased mucus production:
•
•
•
•
Cystic Fibrosis
COPD
Bronchiectasis
Respiratory Infections
• Turberculosis
Mucolysis
• These diseases result in a marked slowing
of mucus transport
• Changes in properties of the mucus
• Decreased ciliary activity
• Both
Mucolytics
• acetylcysteine
• sodium bicarbonate (NaHCO3)
• dornase alfa
• Pulmozyme
Airway Anatomy
Mucus Layer
• Gel (1 to 2 mm): Gelatinous and sticky (flypaper)
• Sol (4 to 8 mm): Watery, Cilia in this layer
• Total layer thickness: 5 to 10 mm thick
• Surface Epithelial Cells
•
•
•
•
Pseudostratified ciliated columnar
Surface goblet cells (6,800/mm2)
Serous cells – Sol layer
Clara cells – Unknown function (enzymes?)
• Submucosal Gland
• Bronchial Gland
Mucus Layer
• Bronchial Gland
•
•
•
•
•
Found in submucosa
Found down to terminal bronchioles
Parasympathetic control (Vagus nerve)
Provide the majority of mucus secretion
Total volume 40 times greater than goblet cells
Mucus vs. Sputum
• Mucus is the total secretion from mucous
membranes including the surface goblet
cell and the bronchial glands.
• Sputum is the expectorated secretions that
contains mucus, as well as oropharyngeal
and nasopharyngeal secretions (saliva).
Mucociliary Escalator
• Mucosal Blanket
• Sol layer
• Gel layer
• Cilia
•
•
•
•
•
200 per cell
6 mm in length
Beat 1000/min
Move mucus 2 cm/min
Paralyzed by cigarette smoke
Viscosity and Elasticity
• Rheology
• Viscosity: Property of a liquid that measures the
resistance to movement when a force is applied.
• Increased viscosity, increased resistance to flow
• Olive oil vs. Water
• Elasticity: Property of solid whereby a solid
changes shape (deforms) when a force is
applied.
• Ideally, a solid is totally elastic, and returns to its
original shape when force is released.
• The mucus layer is ideally very elastic and has a
very low viscosity.
Function of Mucociliary
Escalator
• Protective function
• Remove trapped or inhaled particles and dead
or aging cells.
• Antimicrobial (enzymes in sol/gel)
• Humidification
• Insulation (prevents heat and moisture loss)
• NOTE: No cilia or mucus in lower airways
(respiratory bronchioles on down)
• Mucus also protects the epithelium from
toxic materials.
Structure and Composition of
Mucus
• Composition
• 95% water
• Need for water intake to replenish
• Mucus doesn’t easily absorb water once created
• 3% protein and carbohydrates
• 1% lipids
• Less than 0.3% DNA
Structure and Composition of
Mucus
• Glycoprotein
• Large (macro)molecules
• Strands of polypeptides (protein) that make up
the backbone of the molecule
• String of amino acids
• Carbohydrate side chains
• Chemical bonds “hold” mucus together
• Intramolecular: Dipeptide links
• Connect amino acids
• Intermolecular: Disulfide and Hydrogen bonds
• Connect adjacent macromolecules
Mucus Production
• Normal person produces 100 mL of mucus
per 24 hour period
• Most is reabsorbed back in the bronchial
mucosa
• 10 mL reaches the glottis
• Most of this is swallowed
• Mucus production increases with lung
disease
Increased Mucus Production
•
•
•
•
•
•
Smoking
Environmental irritants
Allergy
Infections
Genetic predisposition
Foreign bodies
Increased Mucus Production
Viscosity of mucus
Ciliary effectiveness
Mucus plugs
Airway Resistance
Infections
Obstructed bronchioles leads to
atelectasis
Diseases that Increase Mucus
Production
•
•
•
•
•
Chronic Bronchitis
Asthma
Cystic Fibrosis
Acute Bronchitis
Pneumonia
• Also some drugs (anticholinergics,
antimuscarinics)
Factors that Impair Ciliary
Activity
•
•
•
•
•
•
•
Endotracheal tubes
Temperature extremes
High FiO2 levels
Dust, Fumes, Smoke
Dehydration
Thick Mucus
Infections
Facilitation of Mucus
Clearance
• Provide adequate hydration
• Increase fluid intake orally or IV
• Remove causative factors
• Smoking, pollution, allergens
• Optimize tracheobronchial clearance
• Use Mucolytics
• Reduce Inflammation
Dairy Intake
• No evidence to support the common belief
that drinking milk increases the production
of mucus or phlegm and congestion in the
respiratory tract
• There is a loose cough associated with
milk intake
Secretion Management
• Increase the depth of the sol layer
• Water
• Saline
• Expectorants
• Alter the consistency of the gel layer
• Mucolytics
• Improve ciliary activity
• Sympathomimetic bronchodilators
• Corticosteroids
Bland Aerosols
• “Dilutes” mucus molecule
• Also known as wetting agents
• Function may be more of an irritant than a wetter
• Types
• Sterile & Distilled Water
• Humectant
• Dense aerosols and asthmatics
• Normal (isotonic) Saline
• Hypertonic Saline
• Increase mucus production
• Hypotonic Saline
Expectorants
• Iodides
• Unclear function
• SSKI (Saturated Solution of Potassium Iodide)
• Guifenesin
• At high doses, stimulates bronchial gland
secretion
• Robitussin
Cough Suppressants
• Vagal stimulation causes a cough.
• Irritation of pharynx, larynx, and bronchi
lead to a reflex cough impulse.
• If the cough is dry and non-productive, it
may be desirable to suppress its activity.
• Cough suppressants depress the cough
center in medulla (?).
• Narcotic preparations (codeine)
• Non-Narcotic preparations (dextromethorphan)
• Caution in patients with thick secretions.
Function of Mucolytics
• Weakening of intermolecular forces binding
adjacent glycoprotein chains
• Disruption of Disulfide Bonds
• Alteration of pH to weaken sugar side
chains of glycoproteins
• Destruction of protein (Proteolysis)
contained in the glycoprotein core of
proteolytic enzymes
• Breaking down of DNA in mucus
Function of Mucolytics
• Disruption of Disulfide Bonds
• acetylcysteine breaks the bonds by substituting a
sulfhydril radical –HS
Function of Mucolytics
• Alteration of pH
• 2% NaHCO3 solutions are used to increase the
pH of mucus by weakening carbohydrate side
chains
• Can be injected directly into the trachea or
aerosolized (2-5 mL)
Function of Mucolytics
• Proteolysis
• Dornase alfa (Pulmozyme)
• Attacks the protein component of the mucus
Hazard of Mucolytics
• The problem with all three mucolytics is
that they destroy the elasticity of mucus
while reducing the viscosity.
• Elasticity is crucial for mucociliary
transport.
• The patient must be able to cough
adequately to remove the mucus.
acetylcysteine
• Indications
• Mucolytic by aerosol or direct instillation into
the ET tube.
• Given orally to reduce liver injury with
acetaminophen (Tylenol) overdose.
• Mix with cola or given by NG tube.
Dosage of acetylcysteine
• Concentration
• 10% or 20%
• Dosage
• 3-5 mL of a 20% solution TID or QID
• Maximum dose 10 mL
• 6-10 mL of a 10% solution TID or QID
• Maximum dose 20 mL
• 1-2 mL of a 10% or 20% for direct
instillation
Hazards of acetylcysteine
• Bronchospasm
• Asthma – may be a problem during an acute
asthma attack.
• Anecdotal; lack of evidence
• If used with asthma, use 10% and mix with a
bronchodilator (preferably a short-acting
agent).
• Increase mucus production
• Be prepared to suction a patient who cannot
cough or who is intubated.
Hazards of acetylcysteine
• Do not mix with antibiotics in the same
nebulizer (incompatible).
• Nausea & Vomiting
• Disagreeable odor (smells like rotten eggs)
due to the hydrogen sulfide.
• Open vials should be used within 96 hours
to prevent contamination.
sodium bicarbonate
• Weak base.
• Increasing the pH of mucus weakens the
polysaccharide chains.
• Available as 1.4%, 5%, and 7.5% solutions.
• Dosage: 2-5 mL of a 2.5% solution Q4-Q8.
• Mix 5% solution with equal volume of sterile
water.
• Can be irritating (especially the 5 & 7.5%
solutions).
dornase alfa
• Pulmozyme
• Clone of the natural human pancreatic
DNase enzyme which digests extracellular
DNA.
• Dornase alfa is a solution of recombinant
human deoxyribonuclease (rhDNase)
• Approved by FDA in 1994
dornase alfa – Pulmozyme
• Indications
• Reduce viscosity of secretions during an
infection by breaking down extracellular DNA.
• Used in cystic fibrosis, chronic bronchitis or
bronchiectasis.
• Maintenance therapy in CF
• Has no effect on non-infected sputum.
Infection
• Increased WBCs – neutrophils
• WBCs contain DNA
• WBCs release DNA when they die which
increases the viscosity of secretions
• Decreases the effectiveness of antibiotics
• Pancreas produces an enzyme called
deoxyribonuclease (DNase) which breaks
down the DNA
•
Function of rhDNase
Concentration and Dosage
•
•
•
•
Supplied in single dose vials (unit dose).
Concentration is 1 mg/mL (0.1% solution).
Each vial contains 2.5 mg /2.5 mL.
Administer one unit dose vial (2.5 mL)
daily.
• Some patients may benefit from BID
administration.
• Do not mix or dilute with other drugs.
• Nebulizer specific (per manufacturer).
Common Side Effect of
Pulmozyme
•
•
•
•
•
Voice Alteration
Pharyngitis/Laryngitis
Rash
Chest pain
Conjunctivitis
• Contraindicated in patients hypersensitive
to Chinese Hamster Ovary cell products.
amiloride
• Midamor
• Diuretic that can be given by aerosol for patients
with cystic fibrosis.
• It is a sodium channel blocker.
• In Cystic Fibrosis, Na+ is absorbed into the
epithelium along with H2O, leaving the mucus
thick and dehydrated.
• By blocking sodium absorption, dehydration of
the mucus is prevented.
• Drug is dissolved in 0.3% NaCl solution and
nebulized.
• Bronchial Asthma (?)
amiloride
denusfosol tetrasodium
• Experimental drug in CF research
• Phase II as of 8/07
• Enhances mucosal hydration and mucus
clearance by activating Cl- secretion and
inhibiting epithelial Na+ transport.
• 28 days of treatment